According to KRChoksey Shares and Securities, Indian pharmaceutical companies’ performance in the US formulations space was remarkable in Q3FY14. The companies have seen steady gain in share in key products in January signalling replication of performance in Q4FY14.
Sun Pharma has gained 99 per cent market share in Lipodox, however, there has been a fall in overall volumes due to lack of promotion by innovator. Company has been able to gain mere four per cent market share in generic Cymbalta. Sandoz is consistently gaining share over Taro in both Nystatin Triamcinolone cream and ointment segment. Prasco Labs has entered Calcitriene ointment market and has gained 31 per cent market share, resulting in an equivalent decline in share for Taro. Sun has gained leadership position in Stalevo and Comtan as Wockhardt’s share slipped post an import alert. Taro’s NDA launch, Topicort spray is steadily gaining market share. Sun’s share in Depo Testorone is still negligible at 0.2 per cent. The company has maintained steady share in two nasal sprays; Azelastine and Desmopressin.
Dr Reddy’s is steadily gaining share in Toprol XL post Wockhardt’s exit from the market. Zenatane continues to gain steady share in the Isotretinoin market, reaching 9.8 per cent this month. The company’s market share in Depakote ER is still in single digit at 6.4 per cent. DRL has lost significant share in Propecia due to entry of new generic players. DRL’s performance in its injectable launches has been incredible with more than 50 per cent market share in generic Reclast and Dacogen and steady gains in Fondaparinux and Vidaza.
Ranbaxy’s Absorica’s share has now steadied at 18 per cent in Isotretinoin market. The drug would have contributed close to 50 per cent to its CY13 EPS. Ranbaxy is fast losing share in Actos, Evoxac and Aricept. The company has gained 55bps market share in generic Caduet which continues to remain a three player market. Ranbaxy has now started gaining share in Pristiq, to four per cent after languishing at one per cent for sizeable period of time. Ranbaxy has gained six per cent market share from Apotex in generic Lipitor.
Lupin has gained second highest market share in generic Cymbalta, due to lack of competition initially. Lupin has gained close to 60 per cent market share in Trizivir, which continues to remain a two player market. Company is fast gaining share in generic Trilipix at 18.2 per cent. Lupin is completely dominating generic Zymaxid market with more than 80 per cent share. They have maintained leadership position in Geodon. The company is consistently losing share in Tricor. Lupin has seen consistent gain in market share in all the oral contraceptives (OCs), with key OCs Yasmin and Seasonique having 12 per cent and 13 per cent market share respectively.
Cadila’s Hospira is consistently losing share in Docetaxel, which is sourced from Zydus-Hospira Oncology facility. The company’s market share in Depakote ER is impressive at 15 per cent even after being a late entrant. The product will be a considerable driver for Cadila even in FY15, due to its complexity. The company has attained 22 per cent share in the third week of Rapamune 0.5g launch; Presence of AG has slowed progress. Cadila’s share in Prevacid DR is still negligible.
Glenmark has consistently lost share in generic Malarone and Cutivate, as Prasco is now becoming aggressive in the market. Company is consistently gaining share in Maxalt MLT, despite increase in competition. Glenmark has seen 98bps jump in market share to 59 per cent in Mupirocin. The company is steadily gaining share in Topicort ointment with market share of 6.6 per cent. It has emerged a strong player in Zomig and Zomig ZMT with close to 35 per cent share. The company is losing traction in the OC space due to lack of new approvals.
Aurobindo’s partner Celtrion has gained a market share of 15.2 per cent in Cymbalta which was key growth driver of its Q3FY14 results. Aurobindo has gained 22 per cent market share in Cefdinir, which was re-launched after approval of Unit VI. However, the company’s share in Modafinil is negligible losing out to Qualitest. The company’s performance in ARV drugs, Abacavir and Combivir has been below expectation. It has gained significant share of 905bps in Singulair Chewable tablet during the month.
EP News Bureau – Mumbai